HPV virus and biomarkers of resistance to chemoradiation in circulating tumor cells from patients with squamous cell carcinoma of the anus

Ruano, Anna Paula Carreta; Costa, Daniela de Jesus Ferreira; Braun, Alexcia Camila; Torres, Jacqueline Aparecida; Barbosa, Pedro Henrique Pereira; Abdallah, Emne Ali; Barberan, Caroline; Silva, Virgílio Souza e; Bovolim, Graziele; Buim, Marcilei Eliza Cavicchioli; Alves, Vanessa da Silva; Riechelmann, Rachel P.; Chinen, Ludmilla Thomé Domingos

doi:10.1016/j.prp.2023.154327

Cited by 2 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the remaining thirty-nine studies, twenty-four studies did not report on ctDNA/cHPV DNA, three were review articles, one was a case report, and one did not focus on anogenital cancer. A total of eight studies were therefore included in the final review [13][14][15][16][17][18][19][20].…”

Section: Search Resultsmentioning

confidence: 99%

“…The eight included studies were published between 2018 and 2023 [13][14][15][16][17][18][19][20]. The number of patients in each individual study ranged from 15 to 251, with a total of 628 patients across the eight studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…DNA biomarkers and detection methods also varied. Six studies assessed the use of ctDNA [13][14][15][16]18,20], of which five examined HPV ctDNA, and one examined multiple single nucleotide variants in ctDNA [13]. The remaining two studies assessed HPV cellfree DNA and circulating free DNA, respectively [17,19].…”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review

Temperley,

Fannon,

O’Sullivan

et al. 2024

IJMS

View full text Add to dashboard Cite

This systematic review investigates the potential of circulating tumour DNA (ctDNA) as a predictive biomarker in the management and prognosis of squamous cell carcinoma of the anal canal (SCCA). PubMed, EMBASE, and Cochrane Central Registry of Controlled Trials were searched until 7 January 2024. Selection criteria included research articles exploring ctDNA in the context of anal cancer treatment response, recurrence risk assessment, and consideration of salvage surgery. A total of eight studies were therefore included in the final review, examining a total of 628 patients. These studies focused on three main themes: SCCA diagnosis and staging, treatment response, and patient outcomes. Significant heterogeneity was observed in terms of patient cohort, study methodology, and ctDNA biomarkers. Four studies provided information on the sensitivity of ctDNA biomarkers in SCCA, with a range of 82–100%. Seven studies noted a correlation between pre-treatment ctDNA levels and SCCA disease burden, suggesting that ctDNA could play a role as a biomarker for the staging of SCCA. Across all seven studies with paired pre- and post-treatment ctDNA samples, a trend was seen towards decreasing ctDNA levels post-treatment, with specific identification of a ‘fast elimination’ group who achieve undetectable ctDNA levels prior to the end of treatment and may be less likely to experience treatment failure. Residual ctDNA detection post-treatment was associated with poorer patient prognosis. This systematic review identifies the broad potential of ctDNA as a useful and decisive tool in the management of SCCA. Further analysis of ctDNA biomarkers that include larger patient cohorts is required in order to clearly evaluate their potential role in clinical decision-making processes.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review

Temperley,

Fannon,

O’Sullivan

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Studies on the clinical application of ctDNA detection for anal cancer had similar designs to the research on OPSCC and cervical cancer. Some authors tried to use this marker to optimally monitor this category of patients, and they expressed the intention to conduct studies on larger cohorts to identify if there is any association between the screening markers of anal cancer and HPV [ 40 ]. Other researchers have already used ctDNA as a biomarker for anal cancer, and they intend to use it further for follow-up on anal cancer therapy [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

“…Lee JY et al, 2020, identified SE = 100%, SP = 100%, PPV = 100%, and NPV = 100% in a study on 33 HPV-positive AC by using a novel NGS assay. None of the analyzed studies reached 100 patients (limits: 2–88 patients) [ 32 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review

Andrioaie,

Luchian,

Dămian

et al. 2023

Pathogens

View full text Add to dashboard Cite

Human papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated HPV infections. Still, even with all of these multidisciplinary interventions, the burden of HPV cancers is still high worldwide. The circulating DNA of HPV-induced cancers is thought to be an adequate biomarker for optimizing the control of these virus-related cancers. We analyzed the literature published in the last 5 years regarding ctDNA and four of the above-mentioned cancers. The most frequently used assay for ctDNA detection was the droplet digital PCR assay, used for the management of therapy in the late stages of cancer. ctDNA could not be used for early detection in any of the studied cancers. The OPSCCs were the most frequent cancers analyzed via ctDNA assays. Larger, properly designed cohort studies might establish the clinical utility of this biomarker.

show abstract

HPV virus and biomarkers of resistance to chemoradiation in circulating tumor cells from patients with squamous cell carcinoma of the anus

Cited by 2 publications

References 28 publications

Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review

Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review

The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review

Contact Info

Product

Resources

About